High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma.

Wen SunShi-Chao LiLi XuWei ZhongZhen-Guang WangChu-Zhi PanJing LiGuang-Zhi JinNa TaWei DongDan LiuHui LiuHong-Yang WangJin Ding

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Sorafenib may be able to delay tumor progression in patients with FLT3-high hepatocellular carcinoma. This potential biomarker needs to be further validated in independent cohorts prior to helping stratify patients for precision therapy in advanced hepatocellular carcinoma.

Keyphrases

acute myeloid leukemia
end stage renal disease
tyrosine kinase
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
poor prognosis
stem cells
mesenchymal stem cells
patient reported outcomes
long non coding rna
cell therapy
bone marrow